Navigation Links
Fox Chase researchers discover a method for clamping down on a cancer-promoting enzyme
Date:4/18/2008

There are many pathways that allow an errant gene to turn a cell cancerous, and a number of these pathways go through a single enzyme called the p21-activated kinase 1, or PAK1.

Researchers at Fox Chase Cancer Center have now identified a molecule capable of shutting down PAK1 before the enzyme becomes active. Previous studies have linked PAK1 activity with breast cancer and have shown the enzyme is important in pathways involving the ras oncogene, which is thought to cause up to 30 percent of all cancers.

In the April 24 issue of the journal Chemistry & Biology, the researchers detail how the molecule, called IPA-3, was found from a screen of nearly 33,000 small molecules, and could serve as a basis for future breast cancer or cancer therapeutics. Cell-based studies using IPA-3 confirm that the molecule is capable of blocking signaling by the PAK1 pathway.

Previous work suggested that hyperactive signaling by PAK1 can contribute to the growth of tumors, but the trick is how to selectively block PAK1 without damaging similar enzymes that are crucial for healthy cellular function, said lead investigator Jeffrey R. Peterson, Ph.D, an associate member of Fox Chase. IPA-3 represents a proof-of-principle, illustrating a new and highly selective approach to targeting PAK1.

PAK1, like all kinases, is an enzyme that regulates other proteins by attaching an energetic molecule to them in a process known as phosphorylation. The active site where the phosphorylation reaction occurs is an attractive target for drug development, since blocking the active site would deactivate the enzyme. Unfortunately, the active site of PAK1 shares a molecular architecture similar to that found in many other kinase enzymes. Previous attempts to inhibit the PAK1 active site chemically have also resulted in inhibiting PAK1-related enzymes, with toxic consequences.

Instead of finding another molecule that binds to the active site, Peterson and his Fox Chase colleagues looked for new molecules that inactivate PAK1 in other ways. The cancer drug Gleevec, for example, is unusually selective for its target by binding to a region outside of the active site that is less common among kinases.

Many other kinases, including PAK1, have unique regions outside the active site that mediate important facets of their function such as localization, substrate recruitment, or regulation, Peterson says. We wondered whether these regions might offer other places for molecules to bind and inhibit PAK1 without affecting other enzymes.

According to Peterson, IPA-3 achieves high selectivity for PAK1 by taking advantage of a unique self-regulating region of the enzyme. The PAK1 protein has an auto-regulatory arm, a structure that PAK1 folds over its own active site when the enzyme is not in use. Their findings suggest that IPA-3 binds to the protein when it is in the closed configuration, which then prevents PAK1 from becoming active.

It is like when the Steve Irwin would subdue a crocodile, he would tape its jaws closed to keep it from biting, Peterson says. Likewise, IPA-3 latches onto PAK1 in a way that prevents PAK1 from exposing its active site.

Peterson and his colleagues, found IPA-3 by screening a library of over 33,000 small molecules for their ability to block phosphorylation by pure PAK1 protein. Any small molecules that blocked PAK1 were noted and were then ranked by potency, reproducibility and commercial availability. IPA-3 came out ahead of the others through this winnowing process, and the researchers then tested IPA-3 to demonstrate that it could also inhibit PAK1 activity inside living cells.

The Fox Chase researchers believe that IPA-3 represents a promising new strategy for creating therapeutics that inhibit PAK1 by mimicking the way cellular enzymes self-regulate in real life, but the IPA-3 molecule itself is not suitable as a therapeutic in its current form. IPA-3 requires further experimental study and refinement before it could become a working drug for humans, Peterson says.


'/>"/>

Contact: Greg Lester
gregory.lester@fccc.edu
215-728-2753
Fox Chase Cancer Center
Source:Eurekalert

Related biology news :

1. U.S. Army and Navy Purchase Over 10,000 New Beretta M9 Pistols
2. U.S. Army and Navy Purchase Over 10,000 New Beretta M9 Pistols
3. McPherson County Kansas to Purchase Stingers
4. Researchers identify proteins involved in new neurodegenerative syndrome
5. Texas researchers and educators head for Antarctica
6. MGH researchers describe new way to identify, evolve novel enzymes
7. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
8. U of MN researchers discover noninvasive diagnostic tool for brain diseases
9. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
10. Researchers discover new strategies for antibiotic resistance
11. Researchers find new taste in fruit flies: carbonated water
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2017)... -- Delta ID Inc., a leader in consumer-grade iris scanning ... CES® 2017. Delta ID has collaborated with Gentex Corporation ... of iris scanning as a secure, reliable and convenient ... car, and as a way to elevate the security ... ID and Gentex will demonstrate (booth #7326 LVCC) a ...
(Date:1/4/2017)... LAS VEGAS , Jan. 4, 2017 /PRNewswire/ ... in performance biometric sensor technology, today announced the ... Benchmark™ sensor systems, the highly-accurate biometric sensor ... ® biometric technology, experience and expertise. The ... of Benchmark designed specifically for hearables, and Benchmark ...
(Date:12/22/2016)... -- As part of its longstanding mission to improve genetic literacy ... released its latest children,s book, titled The One ... topics of inheritance and variation of traits that are part ... school classrooms in the US. The book ... Killoran , whose previous book with 23andMe, You ...
Breaking Biology News(10 mins):
(Date:1/20/2017)... http://www.Financialbuzz.com - According ... causes of death worldwide. There were 8.2 million cancer ... related deaths increased gradually over time, the death rates ... various cancers continues to drive demand of biological therapies ... Market Insights, Inc. cancer biological therapy market size was USD ...
(Date:1/19/2017)... Jan. 19, 2017 /PRNewswire -- WuXi AppTec, a ... capability and technology platform, today announced that it ... focused preclinical drug discovery contract research organization (CRO). ... a wholly-owned subsidiary of WuXi, and will continue ... providing greater services. The acquisition will further strengthen ...
(Date:1/19/2017)... , Jan. 19, 2017  ArmaGen, Inc., ... Schmidt , Ph.D., as chief executive officer, as ... directors. Dr. Schmidt brings to ArmaGen more than 17 ... research and development of biotherapeutics and pharmaceuticals. ... with the diverse experience and skillset necessary to ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... the full spectrum of drug and device development, and Prism Clinical Research ... and clinicians, today announced Verified Clinical Trials (VCT) has been selected ...
Breaking Biology Technology: